Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aggressive treatment of hypertension is effective in reducing both microvascular and macrovascular complications in type 2 diabetes, and target BP less than 130/85 or 130/80 mmHg are now recommended. Inhibition of renin angiotensin aldosterone system (RAAS) plays an essential role in the treatment of hypertension and diabetes-related complications. Studies focusing on renal end-points suggest that angiotensin-converting enzyme inhibitors (ACE-I) are more effective than other traditional agents in reducing the onset of clinical proteinuria in both type 1 and type 2 diabetic patients with incipient nephropathy, mainly in normotensive ones (secondary prevention). However, several small trials in type 2 diabetic patients with overt nephropathy (tertiary prevention) failed to demonstrate a specific renoprotective role for ACE-I, at variance with type 1 diabetes. Three recent large trials address the question of whether angiotensin II receptor blockers (ARB) prevent the development of clinical proteinuria or delay the progression of nephropathy in type 2 diabetes. The IRMA study showed that irbesartan is more effective than conventional therapy in preventing the development of clinical proteinuria and in favoring the regression to normoalbuminuria for comparable BP control in patients with incipient nephropathy. The IDNT and RENAAL trials showed that ARB are more effective than traditional antihypertensive therapies in reducing progression toward end-stage renal failure (ESRF) in type 2 diabetic patients with overt nephropathy independently of changes in BP. Moreover, a reduction in hospitalizations for heart failure was demonstrated for ARB-treated patients compared with placebo. Furthermore, the LIFE study showed that losartan is more effective than conventional therapy in reducing cardiovascular morbidity and mortality in a cohort of diabetic patients with hypertension and left ventricular hypertrophy. In conclusion, ARB seem to be effective in both preventing renal damage and reducing progression toward ESRF in type 2 diabetic patients. Thus, the guidelines for the prevention and treatment of diabetic nephropathy are now changed. In type 1 diabetes ACE-I are the first-choice drug; in type 2 diabetes, ARB are considered first-choice drugs in secondary prevention as well as ACE-I and have been now elected the unique first-choice drug in tertiary prevention of ESRF. Finally, ARB should be considered as the first-choice drug in cardiovascular prevention too, as well as ACE-I.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417
Nielsen, F. S., Rossing, P., Gall, M. A., Skott, P., Smidt, U. M., & Parving, H. H. (1997) · Diabetes · doi:10.2337/diabetes.46.7.1182 · Cited by 182
Martin, M., Neumann, D., Hoff, T., Resch, K., DeWitt, D. L., & Goppelt-Struebe, M. (1994) · Kidney International · doi:10.1038/ki.1994.18 · Cited by 178
Fogari, R., Zoppi, A., Corradi, L., Mugellini, A., Lazzari, P., Preti, P., & Lusardi, P. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000732 · Cited by 96
Cited by
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Durvasula, R. V., Petermann, A. T., Hiromura, K., Blonski, M., Pippin, J., Mundel, P., Pichler, R., Griffin, S., Couser, W. G., & Shankland, S. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00362.x · Cited by 313
“That the beneficial effects of angiotensin II blockade on ameliorating disease are greater than what could be predicted by its hemodynamic effects alone further supports the notion of a pathogenic role for local production of angiotensin II [17, 20].”
BackgroundApproaches to prevention of cardiovascular complications and events in diabetes mellitus
Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139
Yokoyama, H., Matsushima, M., Kawai, K., Hirao, K., Oishi, M., Sugimoto, H., Takeda, H., Minami, M., Kobayashi, M., Sone, H., et al. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03347.x · Cited by 41
Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Quagliaro, L., Piconi, L., Esposito, K., & Giugliano, D. (2004) · Diabetologia · doi:10.1007/s00125-004-1487-3 · Cited by 24
Metadata
- Authors
- Deferrari, G., Ravera, M., Deferrari, L., Vettoretti, S., Ratto, E., & Parodi, D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2002-11
- Volume
- 13
- Issue
- suppl_3
- Pages
- S224-S229
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2097337104
- Cited by
- 53
- References
- 7
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers. https://app.cochat.ai/papers/10.1097/01.asn.0000032544.37147.ae
- The paper
- Deferrari, G., Ravera, M., Deferrari, L., Vettoretti, S., Ratto, E., & Parodi, D. (2002). Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000032544.37147.ae
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.